Page 9 - FLIPBOOK

What we don’t know

• The best order of therapy in CRPC

• Whether ADT + 1 therapy is better

than ADT + 2 therapies in mHSPC

• Whether any biomarker can help us

with drug selection

• Whether PSMA PET detected

metastasis invisible on CT and bone

scan matters

• Whether de novo mHSPC behaves the

same as mHSPC with prior therapy

ADT, androgen deprivation therapy; CRPC, castration-resistant prostate cancer; CT, computed tomography; mHSPC, metastatic hormone-sensitive prostate
cancer; PET, positron emission tomography; PSMA, prostate-specific membrane antigen.
Maurer T, et al. Nat Rev Urol. 2016;13(4):226–35.